$PMVP
PMV Pharmaceuticals, Inc.

2021 Q4 Form 10-K Financial Statement

#000156459022007860 Filed on March 01, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.305M $21.80M $4.320M
YoY Change 45.95% 98.0%
% of Gross Profit
Research & Development $12.17M $36.49M $6.180M
YoY Change 96.88% 52.48%
% of Gross Profit
Depreciation & Amortization $77.00K $307.0K $60.00K
YoY Change 28.33% -3.46% -70.0%
% of Gross Profit
Operating Expenses $18.47M $58.29M $10.50M
YoY Change 75.92% 66.83%
Operating Profit -$58.29M
YoY Change 66.83%
Interest Expense $106.0K $449.0K $50.00K
YoY Change 112.0% -30.92%
% of Operating Profit
Other Income/Expense, Net $7.000K $21.00K $0.00
YoY Change -115.0%
Pretax Income -$18.36M -$57.82M -$10.45M
YoY Change 75.68% 67.94%
Income Tax $0.00 $23.00K $0.00
% Of Pretax Income
Net Earnings -$18.36M -$57.85M -$10.45M
YoY Change 75.68% 67.96%
Net Earnings / Revenue
Basic Earnings Per Share -$1.28
Diluted Earnings Per Share -$404.4K -$1.282M -$233.3K
COMMON SHARES
Basic Shares Outstanding 45.38M 45.14M
Diluted Shares Outstanding 45.14M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $314.1M $297.2M $361.4M
YoY Change -13.1% -17.77% 256.13%
Cash & Equivalents $172.5M $172.5M $361.4M
Short-Term Investments $141.6M $124.7M $0.00
Other Short-Term Assets $4.123M $4.123M $3.300M
YoY Change 24.94% 24.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $301.3M $301.3M $364.8M
YoY Change -17.4% -17.41% 257.28%
LONG-TERM ASSETS
Property, Plant & Equipment $3.090M $13.15M $569.0K
YoY Change 443.06% 2091.67% -23.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $16.91M $16.91M
YoY Change
Other Assets $221.0K $221.0K $201.0K
YoY Change 9.95% 10.5% 0.0%
Total Long-Term Assets $30.28M $30.28M $770.0K
YoY Change 3832.73% 4226.0% -18.09%
TOTAL ASSETS
Total Short-Term Assets $301.3M $301.3M $364.8M
Total Long-Term Assets $30.28M $30.28M $770.0K
Total Assets $331.6M $331.6M $365.5M
YoY Change -9.29% -9.28% 254.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.189M $3.189M $1.607M
YoY Change 98.44% 99.31% -43.36%
Accrued Expenses $8.627M $9.030M $4.803M
YoY Change 79.62% 88.13% 184.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.22M $12.22M $6.410M
YoY Change 90.62% 90.92% 41.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.79M $10.79M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $10.79M $10.79M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.22M $12.22M $6.410M
Total Long-Term Liabilities $10.79M $10.79M $0.00
Total Liabilities $23.01M $23.01M $6.410M
YoY Change 258.95% 259.52% 40.14%
SHAREHOLDERS EQUITY
Retained Earnings -$167.7M -$109.9M
YoY Change 52.64% 45.65%
Common Stock $476.4M $469.0M
YoY Change 1.57% 9338.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $308.6M $308.6M $359.1M
YoY Change
Total Liabilities & Shareholders Equity $331.6M $331.6M $365.5M
YoY Change -9.29% -9.28% 254.77%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$18.36M -$57.85M -$10.45M
YoY Change 75.68% 67.96%
Depreciation, Depletion And Amortization $77.00K $307.0K $60.00K
YoY Change 28.33% -3.46% -70.0%
Cash From Operating Activities -$12.03M -$46.57M -$10.31M
YoY Change 16.66% 42.25% -5.06%
INVESTING ACTIVITIES
Capital Expenditures -$262.0K $1.349M -$60.00K
YoY Change 336.67% 811.49% 500.0%
Acquisitions
YoY Change
Other Investing Activities $7.821M -$142.2M $0.00
YoY Change -606.9% -100.0%
Cash From Investing Activities $7.559M -$143.6M -$60.00K
YoY Change -12698.33% -614.44% -99.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 295.0K 2.022M -1.360M
YoY Change -121.69% -99.31% -102.2%
NET CHANGE
Cash From Operating Activities -12.03M -46.57M -10.31M
Cash From Investing Activities 7.559M -143.6M -60.00K
Cash From Financing Activities 295.0K 2.022M -1.360M
Net Change In Cash -4.174M -188.1M -11.73M
YoY Change -64.42% -165.29% -137.46%
FREE CASH FLOW
Cash From Operating Activities -$12.03M -$46.57M -$10.31M
Capital Expenditures -$262.0K $1.349M -$60.00K
Free Cash Flow -$11.77M -$47.92M -$10.25M
YoY Change 14.79% 45.71% -5.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001699382
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 us-gaap Open Tax Year
OpenTaxYear
2013 2014 2015 2016 2017 2018 2019 2020 2021
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y7D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M17D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M9D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y10M9D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0035
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0031
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0149
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0130
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0151
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0251
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7650
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7070
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7207
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7990
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7760
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7269
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021Q2 dei Entity Public Float
EntityPublicFloat
1229389330
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45433684
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45433684
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
308559000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
331568000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36493000
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
172467000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
361422000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
822000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
124696000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3301000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3339000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
301286000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
364761000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3090000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
569000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
16911000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10060000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
221000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
201000
CY2021Q4 us-gaap Assets
Assets
331568000
CY2020Q4 us-gaap Assets
Assets
365531000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3189000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1607000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8627000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4803000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
403000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12219000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6410000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10790000
CY2021Q4 us-gaap Liabilities
Liabilities
23009000
CY2020Q4 us-gaap Liabilities
Liabilities
6410000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44777818
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44777818
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
476363000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
469001000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167726000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109880000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-78000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
359121000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
365531000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23933000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20759000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21800000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11009000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5878000
CY2021 us-gaap Operating Expenses
OperatingExpenses
58293000
CY2020 us-gaap Operating Expenses
OperatingExpenses
34942000
CY2019 us-gaap Operating Expenses
OperatingExpenses
26637000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-58293000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-34942000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-26637000
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
651000
CY2019 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1301000
CY2019 pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-8000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45137656
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-46140000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
100000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
908000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-25352000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-70474000
CY2020 pmvp Reclassifications Of Temporary To Permanent Equity Shares
ReclassificationsOfTemporaryToPermanentEquityShares
-28188110
CY2020 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
-238723000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
238723000
CY2020 pmvp Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
194000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
223176000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1933000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-34440000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
359121000
CY2021 pmvp Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans
ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
2022000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5340000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-57846000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-78000
CY2021 us-gaap Profit Loss
ProfitLoss
-57846000
CY2020 us-gaap Profit Loss
ProfitLoss
-34440000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
5340000
CY2019 us-gaap Depreciation
Depreciation
388000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-152000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-62000
CY2021 pmvp Other Non Cash Lease Expense
OtherNonCashLeaseExpense
974000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
19000
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-143000
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-8000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-38000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2732000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
275000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
191000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1230000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1799000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3894000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3117000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
397000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46571000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32739000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22065000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1349000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
148000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
109000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
256845000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
14512000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
43452000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
114610000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
42571000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
46792000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-143584000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27911000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3231000
CY2020 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
69790000
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
61705000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
223176000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2022000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2022000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
292972000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61805000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-188133000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
288144000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42971000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
361422000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73278000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30307000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
173289000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
361422000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73278000
CY2021 pmvp Lease Incentives Used For Leasehold Improvements
LeaseIncentivesUsedForLeaseholdImprovements
-88000
CY2021 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1391000
CY2020 pmvp Conversion Of Convertible Preferred Stock To Common Stock
ConversionOfConvertiblePreferredStockToCommonStock
238723000
CY2020 pmvp Conversion Of Warrant Liability To Common Stock
ConversionOfWarrantLiabilityToCommonStock
194000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
23000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
8000
CY2020Q3 pmvp Proceeds From Issuance Of Common Stock Gross
ProceedsFromIssuanceOfCommonStockGross
243536000
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
223176000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-57846000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46571000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167726000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
314074000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses, and the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including expense, the supply chain, clinical trials, research and development costs, and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of the COVID-19 pandemic within our consolidated financial statements and there may be changes to those estimates in future periods.</p>
CY2021 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
5.2651-for-1 reverse stock split of the Company’s common stock and convertible preferred stock
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
550000
CY2020 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
152000
CY2019 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
62000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
822000
CY2021 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
five years
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-78000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3000
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
10000
CY2021Q4 us-gaap Cash
Cash
3508000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
168960000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
360041000
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
141607000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
124696000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
16911000
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4958000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2130000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1868000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1561000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3090000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
569000
CY2021 us-gaap Depreciation
Depreciation
307000
CY2020 us-gaap Depreciation
Depreciation
318000
CY2021Q4 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
0
CY2020Q4 pmvp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
1595000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
96000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
99000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8627000
CY2021Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3797000
CY2020Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3109000
CY2021Q4 pmvp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
4734000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4803000
CY2018Q3 pmvp Number Of Noncancelable Operating Leases
NumberOfNoncancelableOperatingLeases
2
CY2021 pmvp Number Of Members Of Board Of Directors Elected By Holders Of Preferred Stock Voting As Single Class
NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfPreferredStockVotingAsSingleClass
4
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1691000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
704000
CY2021 us-gaap Lease Cost
LeaseCost
2395000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10060000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
403000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10790000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11193000
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
717000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10318000
CY2021Q4 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths
-2609000
CY2021Q4 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Two
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo
1833000
CY2021Q4 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Three
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree
1814000
CY2021Q4 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Four
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour
1869000
CY2021Q4 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Five
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFive
1925000
CY2021Q4 pmvp Lessee Operating Lease Liability To Be Paid Net Of Repayments After Year Five
LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFive
11477000
CY2021Q4 pmvp Lessee Operating Lease Liability Payments Net Of Repayments Due
LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue
16309000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5116000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11193000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1691000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
561000
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
22866246
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
22866246
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
22883426
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
168933000
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
169385000
CY2019Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
22866246
CY2019 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00001
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
22866246
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
22866246
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
22883426
CY2021 pmvp Number Of Members Of Board Of Directors Elected By Holders Of Common Stock Voting As Single Class
NumberOfMembersOfBoardOfDirectorsElectedByHoldersOfCommonStockVotingAsSingleClass
2
CY2021 us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
Each share of Preferred Stock automatically converts to the number of shares of common stock determined in accordance with the conversion rate upon the earlier of (i) written consent of two-thirds of the then outstanding shares of Preferred Stock, voting together as a single class, and written consent of the majority of the then outstanding shares of Series C Preferred or (ii) the closing of a public offering, in which the gross cash proceeds are at least $40,000 and the initial offering price to the public is at least $11.3121 per share (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations, reorganizations, reclassifications or the like).
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45433684
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45433684
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44777818
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44777818
CY2021 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4951680
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4609725
CY2021Q4 pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan
801464
CY2020Q4 pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForEmployeeStockPurchasePlan
400752
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9999151
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9101447
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4609725
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4090970
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.14
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
238792000
CY2021 pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Reserved For Issuance
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance
1343334
CY2021 pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
807180
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
807180
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
29.22
CY2021 pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
43343
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
43343
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.89
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
608800
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.03
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4951680
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4246007
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.22
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
68506000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4246007
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.22
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
68506000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2668149
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.48
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
52952000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
15708000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5340000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1933000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
908000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
23000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
6000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
8000
CY2021 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
23000
CY2020 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
6000
CY2019 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
8000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.09
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.08
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.07
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.03
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.02
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.01
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.05
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.37
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.30
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.29
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
45231000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27511000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1587000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
748000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
4593000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2891000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
45000
CY2021Q4 pmvp Deferred Tax Liabilities Operating Leases
DeferredTaxLiabilitiesOperatingLeases
2854000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
37000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
45000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2891000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25644914
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2414000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1033000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
830000
CY2021Q4 pmvp Deferred Tax Assets Operating Leases
DeferredTaxAssetsOperatingLeases
3175000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
55619000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
31503000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
52728000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31458000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
45000
CY2021Q4 pmvp Operating Loss Carryforwards Begin To Expire In Future Amount
OperatingLossCarryforwardsBeginToExpireInFutureAmount
27515000
CY2021 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
Net operating loss carryforwards related to tax years after 2017 of $132,371 do not expire.
CY2021Q4 pmvp Operating Loss Carryforwards Amounts Do Not Expire
OperatingLossCarryforwardsAmountsDoNotExpire
132371000
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1654000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
877000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
877000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
543000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
43000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
5000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
734000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
329000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1654000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
877000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4246007
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4090970
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-57846000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-34440000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-25352000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45137656
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14364475
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3035243
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.28
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.40
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.35
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania

Files In Submission

Name View Source Status
0001564590-22-007860-index-headers.html Edgar Link pending
0001564590-22-007860-index.html Edgar Link pending
0001564590-22-007860.txt Edgar Link pending
0001564590-22-007860-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g5rlbv12cydj000001.jpg Edgar Link pending
g5rlbv12cydj000002.jpg Edgar Link pending
gfifg3pi0xun000001.jpg Edgar Link pending
gfifg3pi0xun000002.jpg Edgar Link pending
gv1ubg3hw41v000001.jpg Edgar Link pending
gv1ubg3hw41v000002.jpg Edgar Link pending
gv1ubg3hw41v000003.jpg Edgar Link pending
gv1ubg3hw41v000004.jpg Edgar Link pending
gv1ubg3hw41v000005.jpg Edgar Link pending
gv1ubg3hw41v000006.jpg Edgar Link pending
gv1ubg3hw41v000007.jpg Edgar Link pending
gv1ubg3hw41v000008.jpg Edgar Link pending
gv1ubg3hw41v000009.jpg Edgar Link pending
gv1ubg3hw41v000010.jpg Edgar Link pending
gv1ubg3hw41v000011.jpg Edgar Link pending
gv1ubg3hw41v000012.jpg Edgar Link pending
gv1ubg3hw41v000013.jpg Edgar Link pending
gv1ubg3hw41v000014.jpg Edgar Link pending
gv1ubg3hw41v000015.jpg Edgar Link pending
gv1ubg3hw41v000016.jpg Edgar Link pending
gw0ad20d1dfx000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pmvp-10k_20211231.htm Edgar Link pending
pmvp-10k_20211231_htm.xml Edgar Link completed
pmvp-20211231.xsd Edgar Link pending
pmvp-20211231_cal.xml Edgar Link unprocessable
pmvp-20211231_def.xml Edgar Link unprocessable
pmvp-20211231_lab.xml Edgar Link unprocessable
pmvp-20211231_pre.xml Edgar Link unprocessable
pmvp-ex1014_338.htm Edgar Link pending
pmvp-ex1017_538.htm Edgar Link pending
pmvp-ex108_331.htm Edgar Link pending
pmvp-ex211_332.htm Edgar Link pending
pmvp-ex231_918.htm Edgar Link pending
pmvp-ex311_537.htm Edgar Link pending
pmvp-ex312_335.htm Edgar Link pending
pmvp-ex321_336.htm Edgar Link pending
pmvp-ex322_337.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending